Cargando…
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
Autores principales: | Goel, Utkarsh, Charalampous, Charalampos, Kapoor, Prashant, Binder, Moritz, Buadi, Francis K., Dingli, David, Dispenzieri, Angela, Fonder, Amie, Gertz, Morie A., Gonsalves, Wilson I., Hayman, Suzanne R., Hobbs, Miriam A., Hwa, Yi L., Kourelis, Taxiarchis, Lacy, Martha Q., Leung, Nelson, Lin, Yi, Warsame, Rahma M., Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834217/ https://www.ncbi.nlm.nih.gov/pubmed/36631454 http://dx.doi.org/10.1038/s41408-023-00785-y |
Ejemplares similares
-
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023) -
P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022) -
P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022) -
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022) -
P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES
por: Charalampous, Charalampos, et al.
Publicado: (2023)